Amyotrophic lateral sclerosis (ALS) is a progressive disorder that affects motor neurons responsible for controlling voluntary muscle movement. As these nerve cells degenerate, patients gradually lose the ability to walk, speak, swallow, and eventually breathe independently. Although a small proportion of cases are linked to inherited genetic mutations, most ALS diagnoses occur sporadically, with no single identifiable cause. Researchers increasingly view ALS as a complex, multi-factor disease involving overlapping mechanisms such as protein aggregation,
neuroinflammation, mitochondrial dysfunction, and impaired cellular repair processes. This biological complexity has made drug development particularly challenging, contributing to decades of limited therapeutic progress.
Current treatment strategies focus largely on slowing disease progression and managing symptoms rather than reversing neuronal damage. Key therapeutics include Riluzole, a cornerstone therapy that acts to reduce glutamate-mediated excitotoxicity, which is believed to contribute to motor neuron death; and Edaravone, introduced more recently, which targets oxidative stress and may help preserve physical function in some patients, though responses can vary. Alongside these therapies, supportive multidisciplinary care plays a critical role in extending
survival and maintaining quality of life. Respiratory support, nutritional interventions, and assistive communication technologies have significantly improved patient outcomes even in the absence of curative treatments. Meanwhile, emerging approaches, including gene-targeted therapies, antisense oligonucleotides, and anti-inflammatory agents, aim to address specific biological drivers of the disease rather than its symptoms alone.
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Clinical research activity has expanded considerably. Trial activity reached its highest level in 2025, which accounted for roughly 9% of all studies, suggesting an accelerating interest in novel therapeutic approaches. In terms of clinical trial status, approximately 59% of trials have been completed, 9% are currently ongoing and recruiting participants, while another 9% are planned. A further 5% are ongoing but no longer recruiting, and approximately 17% have been suspended, terminated, or withdrawn.
Geographically, research activity is concentrated in several leading markets. The US has the largest share of trial sites with approximately 32%, followed by China with about 13%. Japan, Canada, and Italy contribute close to 8% each. This broad international participation reflects both the global burden of ALS and increasing collaboration across academic institutions, biotechnology companies, and public health systems. As larger and more targeted studies continue to emerge, analysts are watching closely to see whether advances in genetics and precision medicine can finally translate into durable clinical benefits for patients living with this devastating disease.
